Travere Therapeutics CLO Elizabeth Reed sells $2.34m in stock

Travere Therapeutics' Chief Legal Officer, Elizabeth Reed, sold $2.34 million worth of the company's common stock on September 15, 2026. The sales took place at prices spanning from $62.0255 to $65.31 per share, occurring as the stock approached its 52-week high of $68.73, following a 168% increase over the past year. Despite this, the stock was deemed overvalued relative to its Fair Value according to InvestingPro analysis.

On the same day, Reed acquired 37,500 shares through the exercise of employee stock options, purchased at $15.46 each, totaling $579,750. The transactions were carried out according to a pre-arranged trading plan implemented on June 16, 2026. As a result of these actions, Reed's direct ownership in Travere Therapeutics now amounts to 105,389 shares.